Description
Introduction:
Exenatide or Extendin-4 is a potent GLP-1 receptor agonist. Exenatide (marketed as Byetta) is one of a new class of medications (incretin mimetics) approved (in April 2005) for the treatment of diabetes mellitus type 2 (It was not approved for use in diabetes mellitus type 1).
Intended Use:
The KRIBIOLISA Exenatide ELISA is used as for the quantitative determination of Exenatide in serum, plasma and cell culture supernatant.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Exenatide are pre-coated onto microwells. Samples and standards are pipetted into microwells and Exenatide present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated antiExenatide antibody is pipetted and incubated with samples. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Exenatide in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!